CD47 monoclonal antibody is beginning to show its strength!

In 2020, a local biopharmaceutical company and the world's top ten pharmaceutical companies AbbVie reached a strategic cooperation worth nearly 3 billion U.

Tianjing Biology (NASDAQ: IMAB) is committed to the target biology research of innovative biological drugs, antibody technology, and clinical development and product commercialization in China and the United States.

April 7, 2021, the day held throughout 2021 investor biological R & D Day, many bio-day environment management layer to share the latest developments in a number of important research and development pipeline in this event, and announced a future development strategy.

• The first product, the CD38 antibody fezetuzumab (TJ202), is expected to submit a new drug application in the fourth quarter of 2021.
  
  

  Lemzoparlimab is an innovative CD47 monoclonal antibody independently developed by Tianjing Biotechnology for the treatment of various cancers.

  
  

  Lemzoparlimab (TJC4) blocks the CD47 pathway so that tumors can be phagocytosed by macrophages, promotes anti-tumor T cell immune response, and has the potential to become a therapeutic option in the field of tumor immunity .

  
  Immune Tumor Immune has observed single-agent efficacy in solid tumors, and the dose climbs up to 30mg/kg without hematological toxicity, and the performance is excellent.
  
  

  At the SITC 2020 meeting, Tianjing Bio announced the preliminary data of lemzoparlimab monotherapy for solid tumors (20 patients), covering 9 tumor types

  At the SITC 2020 meeting, Tianjing Bio announced the preliminary data of lemzoparlimab monotherapy for solid tumors (20 patients), covering 9 tumor types

  Speaking Lemzoparlimab, day environment biological founder and chairman Dr.

  
  Dr.
  
  Heavens has completed Uliledlimab biological and import monotherapy with natalizumab Lee (Tai Shengqi for A ^® ) clinical studies on patients with solid tumors in the United States Ⅰ, and (in 2021 the American Society of Clinical Oncology ASCO ) annual meeting Announce the detailed data of the clinical study.
  
  Gastric pancreatic FDA has approved the launch of TJ-CD4B / ABL111 of Ⅰ clinical trials of investigational new drug application for FDA has approved the launch of TJ-CD4B / ABL111 of Ⅰ clinical trials of investigational new drug application for FDA

  Also present at this event were many management personnel including Dr.

  
  Dr.
  Shen Huaqiong, CEO of Tianjing Bio, Zhu Yifei, Chief Commercial Officer, and many other management personnel, well-known industry experts, Professor Dong Chen, Academician of the Chinese Academy of Sciences, Professor Ma Jun, Chinese Society of Clinical Oncology, Professor Shen Lin, Vice President of Peking University Cancer Hospital,
  
  leave a message here